Justification for species selection for pharmaceutical toxicity studies
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Toxicity studies using mammalian species are generally required to provide safety data to support clinical development and licencing registration for potential new pharmaceuticals. International regulatory guidelines outline recommendations for the order (rodent and/or non-rodent) and number of species, retaining flexibility for development of a diverse range of drug modalities in a manner relevant for each specific new medicine. Selection of the appropriate toxicology species involves consideration of scientific, ethical and practical factors, with individual companies likely having different perspectives and preferences regarding weighting of various aspects dependent upon molecule characteristics and previous experience of specific targets or molecule classes. This article summarizes presentations from a symposium at the 2019 Annual Congress of the British Toxicology Society on the topic of species selection for pharmaceutical toxicity studies. This symposium included an overview of results from a National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) and Association of British Pharmaceutical Industry (ABPI) international collaboration that reviewed the use of one or two species in regulatory toxicology studies and justification for the species selected within each programme. Perspectives from two pharmaceutical companies described their processes for species selection for evaluation of biologics, and justification for selection of the minipig as a toxicological species for small molecules. This article summarizes discussions on the scientific justification and other considerations taken into account to ensure the most appropriate animal species are used for toxicity studies to meet regulatory requirements and to provide the most value for informing project decisions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164 · cited 1×
“downstream signalling between humans and NHPs, which ultimately led to extensive, life-threatening toxicities in the first patients dosed [35] due to a severe Cytokine Release Syndrome (Cytokine storm).”
BackgroundConcordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050 · cited 1×
“Data from these species have contributed to safe administration in humans for the majority of drugs in development, with reasonable predictivity for likely adverse events in those molecules that achieved entry into the clinic [13, 25, 26].”
BackgroundMonticello, T. M., Jones, T. W., Dambach, D. M., Potter, D. M., Bolt, M. W., Liu, M., Keller, D. A., Hart, T. K., & Kadambi, V. J. (2017) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2017.09.006 · Cited by 186 · cited 2×
“The most common species tend to be rat and dog [11, 12], although non-human primates (NHPs) are also widely used as the non-rodent [13].”
Backgroundvan Gerven, J., & Bonelli, M. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13550 · Cited by 162
A big data approach to the concordance of the toxicity of pharmaceuticals in animals and humans
Clark, M., & Steger-Hartmann, T. (2018) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2018.04.018 · Cited by 162
Brennan, F. R., Cavagnaro, J., McKeever, K., Ryan, P. C., Schutten, M. M., Vahle, J., Weinbauer, G. F., Marrer-Berger, E., & Black, L. E. (2018) · mAbs · doi:10.1080/19420862.2017.1389364 · Cited by 70
The ability of animal studies to detect serious post marketing adverse events is limited
van Meer, P. J. K., Kooijman, M., Gispen-de Wied, C. C., Moors, E. H. M., & Schellekens, H. (2012) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2012.09.002 · Cited by 66
Bailey, J., & Balls, M. (2019) · BMC Medical Ethics · doi:10.1186/s12910-019-0352-3 · Cited by 51 · cited 1×
“debate the topic of predictivity or whether any of the toxicology species may be more useful than another [27, 28], but to provide examples for the scientific justification of the species chosen,”
Background
Cited by
Carratt, S. A., Zuch de Zafra, C. L., Oziolor, E., Rana, P., Vansell, N. R., Mangipudy, R., & Vaidya, V. S. (2025) · Toxicological Sciences · doi:10.1093/toxsci/kfae122 · Cited by 59
Exploring rabbit as a nonrodent species for general toxicology studies
Sokolowski, K., Turner, P. V., Lewis, E., Wange, R. L., & Fortin, M. C. (2024) · Toxicological Sciences · doi:10.1093/toxsci/kfae022 · Cited by 17
Wright, P. S. R., Briggs, K. A., Thomas, R., Smith, G. F., Maglennon, G., Mikulskis, P., Chapman, M., Greene, N., Phillips, B. U., & Bender, A. (2023) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2022.105308 · Cited by 8
A novel computational machine learning pipeline to quantify similarities in 3D protein structures
Hirway, S. U., Xu, X., & Fan, F. (2025) · Toxicological Sciences · doi:10.1093/toxsci/kfaf007
Metadata
- Authors
- Prior, H., Haworth, R., Labram, B., Roberts, R., Wolfreys, A., & Sewell, F.
- Venue
- Toxicology Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-11-24
- Volume
- 9
- Issue
- 6
- Pages
- 758-770
- ISSN
- 2045-452X (ISSN-L)
- 2045-4538
- OpenAlex
- W3111905213
- Cited by
- 85
- References
- 8
- FWCI
- 7.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.